The objectives for this 2 Part study are to assess the safety, tolerability, and pharmacokinetics following single ascending oral doses of nacresertib in healthy adult participants (Part 1) and to assess the safety, tolerability, and pharmacokinetics following multiple ascending oral doses in healthy adult participants (Part 2).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Maximum Observed Plasma Concentration (Cmax) of nacresertib
Timeframe: Up to Day 19
Time to Cmax (Tmax) of nacresertib
Timeframe: Up to Day 19
Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to the Time of the Last Measurable Concentration (AUCt) of nacresertib
Timeframe: Up to Day 19
AUC From Time 0 to the Time Infinity (AUCinf) of nacresertib
Timeframe: Up to Day 19
Part 2 Only: Area under the Plasma Concentration-time Curve from Time Zero to the End of the Dosing Interval (AUCtau) of nacresertib
Timeframe: Up to Day 14
Terminal Phase Elimination Rate Constant (Beta) of nacresertib
Timeframe: Up to Day 19
Terminal Phase Elimination Half-Life (t1/2) of nacresertib
Timeframe: Up to Day 19
Dose Normalized Cmax
Timeframe: Up to Day 19
Dose Normalized AUCs
Timeframe: Up to Day 19
Number of Participants Experiencing Adverse Events (AEs)
Timeframe: 74 Days